LONDON, May 20, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be giving two presentations today at the 13th Annual Pain Therapeutics Conference on May 20th, 2013, in London, UK.
Immediately following the Chairman's opening remarks for the conference, Dr. Yeomans will be giving his first presentation, "Use of DNA Directed RNA Interference as a New Approach to Long Term Pain Therapy," at 9:10 AM GMT on Monday, May 20th. The presentation will focus on the advantages of using gene silencing techniques for the development of novel and targeted pain therapeutics, as well as highlight the progress made and current challenges facing pain researchers.
Trigemina's lead product candidate, TI-001, an intranasal oxytocin therapy, will be featured in Dr. Yeomans' second presentation, "A Novel Target for Chronic Migraine Therapy: A Clinical Demonstration of Nasal Oxytocin Efficacy and Safety," on Monday, May 20th at 4:00 PM GMT. During this presentation, Dr. Yeomans will be sharing the results of their chronic migraine trial, as well as going in-depth on the mechanism of action for the Company's pain therapeutic.
"Previous research has shown that receptors for the hormone oxytocin are present on the pain-sensing trigeminal neurons at significantly higher levels in patients with chronic head pain, such as chronic migraine or trigeminal neuralgia," stated Dr. Yeomans. "The nasal application of TI-001 allows for a concentrated and targeted delivery of oxytocin to the trigeminal system, which produces a potent, but safe, analgesic effect something many of these patients haven't experienced in years."
Later this week, Dr. Yeomans will be giving a poster presentation at the International Congress on Neuropathic Pain on May 23rd-26th, 2013, in Toronto, Canada. The presentation will explore preclinical work with TI-001 for the treatment of trigeminal neuralgia, which is also known as the suicide disease, a severe nerve disorder that causes episodes of intense facial pain.
TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
For additional information, please visit www.trigemina.com
The Ruth Group
Aaron Estrada (media)
SOURCE Trigemina, Inc.
Help employers find you! Check out all the jobs and post your resume.